Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Colorcon

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Choline fenofibrate - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for choline fenofibrate and what is the scope of patent protection?

Choline fenofibrate is the generic ingredient in two branded drugs marketed by Actavis Elizabeth, Alembic Pharms Ltd, Anchen Pharms, Aurobindo Pharma Ltd, Graviti Pharms, Impax Labs Inc, Lupin Ltd, Mylan Pharms Inc, Twi Pharms, and Abbvie, and is included in ten NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Choline fenofibrate has nineteen patent family members in eleven countries.

There are one hundred and two drug master file entries for choline fenofibrate. Eleven suppliers are listed for this compound.

Recent Clinical Trials for choline fenofibrate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Daewon Pharmaceutical Co., Ltd.Phase 4
Essentialis, Inc.Phase 2
Medpace, Inc.Phase 2

See all choline fenofibrate clinical trials

Recent Litigation for choline fenofibrate

Identify potential future generic entrants

District Court Litigation
Case NameDate
ABBOTT LABORATORIES v. WATSON LABORATORIES, INC.-FLORIDA2010-04-27

See all choline fenofibrate litigation

Pharmacology for choline fenofibrate
Synonyms for choline fenofibrate
1034151-05-7
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate,2-hydroxyethyl(trimethyl)azanium
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid choline salt
2-Hydroxy-N,N,N-trimethylethanaminium 2-(-(4-chlorobenzoyl)phenoxy)-2- methylpropanoate
2-Hydroxy-N,N,N-trimethylethanaminium 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
2-Hydroxy-N,N,N-trimethylethanaminium 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
2-Hydroxy-N,N,N-trimethylethanaminium2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
3320AC
4BMH7IZT98
856676-23-8
ABT 335
Abt 335;abt-335;abt335
ABT-335
AKOS016010592
API0009427
AS-10210
AX8245113
BCP28592
CHEMBL1201745
Choline fenofibrate (ABT-335)
Choline fenofibrate (USAN/INN)
Choline fenofibrate [USAN:INN]
CS-0893
CTK8E8257
D08890
DTXSID50234939
Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-(4-(4- chlorobenzoyl)phenoxy)-2-methylpropanoic acid (1:1)
Fenofibrate de choline
Fenofibric acid (TN)
FT-0665026
HIP0901
HY-14739
JWAZHODZSADEHB-UHFFFAOYSA-M
KS-00000R22
MolPort-006-393-282
RT-012006
ST24040685
Trilipix
UNII-4BMH7IZT98
Unii-4bmh7izt98 BFenofibrate de choline
W-5743
Paragraph IV (Patent) Challenges for CHOLINE FENOFIBRATE
Tradename Dosage Ingredient NDA Submissiondate
TRILIPIX CAPSULE, DELAYED RELEASE;ORAL choline fenofibrate 022224 2009-09-02
TRILIPIX CAPSULE, DELAYED RELEASE;ORAL choline fenofibrate 022224 2009-09-01

US Patents and Regulatory Information for choline fenofibrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anchen Pharms FENOFIBRIC ACID choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 201573-001 Jul 18, 2013 AB RX No No   Start Trial   Start Trial   Start Trial
Actavis Elizabeth FENOFIBRIC ACID choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 200920-002 Oct 7, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Graviti Pharms FENOFIBRIC ACID choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 211626-001 Jul 18, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Alembic Pharms Ltd FENOFIBRIC ACID choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 208705-001 May 12, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Lupin Ltd FENOFIBRIC ACID choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 200750-001 Dec 4, 2013 AB RX No No   Start Trial   Start Trial   Start Trial
Impax Labs Inc FENOFIBRIC ACID choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 200264-002 Sep 7, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for choline fenofibrate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1746976 CA 2017 00030 Denmark   Start Trial PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018
1758590 300907 Netherlands   Start Trial PRODUCT NAME: DEOXYCHOLINEZUUR NATRIUMZOUT
0050793 94C0009 Belgium   Start Trial PRODUCT NAME: COLFOSCERIL PALMITAS (DIPALMITOYLPHOSPHATIDYLCHOLINE) (DPPC); NAT REG.: 251 IS 142 F 12; FIRST REG.: GB PL 0003/0283 19901214
1746976 LUC00026 Luxembourg   Start Trial PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
1746976 2017C/027 Belgium   Start Trial PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Express Scripts
Boehringer Ingelheim
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.